Liver Cancer/HCC
Liver Cancer/HCC
Liver Cancer Increasing among People with HIV/HCV Coinfection
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
Hepatocellular carcinoma (HCC) is a growing problem among HIV positive people coinfected with hepatitis C virus (HCV) in Spain, and it is often diagnosed at a late stage when it is difficult to treat, researchers reported in the January 1, 2013, issue of Clinical Infectious Diseases.
AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 04 December 2012 00:00
- Written by Liz Highleyman
Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
Coverage of the 2012 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com AASLD 2012 conference section
11/13/12
AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 30 November 2012 00:00
- Written by Liz Highleyman
The investigational cancer drug brivanib did not significantly increase overall survival for patients with hepatocellular carcinoma compared with existing standard therapy, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this month in Boston. But another drug, tivatinib, did appear beneficial for a subset of patients. 
Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee
- Details
- Category: Hepatitis B
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases Liver Meeting is the premier annual U.S. conference on 
hepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Kicking off the meeting on Saturday, AASLD President Guadalupe Garcia-Tsao offered a media overview of some highlights selected from the more than 2000 abstracts to be presented during the week.
More Articles...
- Antiviral Therapy for Hepatitis C, Especially with Sustained Response, Lowers Liver Cancer Risk
- EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
- Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
- Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients
Web Design and Development by